This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pluristem Joins Both The TA-75 And TA-100 Indexes On The Tel Aviv Stock Exchange

HAIFA, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has been informed by the Tel Aviv Stock Exchange (TASE) that its shares are now listed in both the Tel-Aviv-75 (TA-75) and the Tel Aviv-100 (TA-100) Index effective December 16, 2012. The TA-100 index tracks the top 100 companies listed on TASE weighted by market capitalization.

"We are proud to be included in this important Tel Aviv Stock Exchange index and to become one of the 100 most highly capitalized companies on the exchange," said Zami Aberman, Chairman and CEO of Pluristem. "Our inclusion in this index positions us as one of the top Israeli-based biotechnology companies and is another step in our evolution as a leading global publicly traded biotech company. Additionally, this designation places us on the radar screen of many Israeli fund managers, in particular those who follow and track this index."

About TA-75

The TA-75 Index is one of the TASE's leading indices, published from 1999. The index tracks the 75 shares with the highest market capitalization not included in the TA-25 index.

About TA-100

The TA-100 Index is one of the TASE's leading indices, published from 1992. The index consists of the 100 shares with the highest market capitalization that are included in the TA-25 and TA-75 indices.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 17,753.36 +123.09 0.70%
S&P 500 2,103.95 +10.70 0.51%
NASDAQ 5,095.9550 +6.7490 0.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs